dedicated to treating pain and combating the opioid epidemic;
and
WHEREAS, Fathom Pharma's main laboratory is located in
Hummelstown; and
WHEREAS, Fathom Pharma is developing a long-acting injectable
pain relief (LAIPR) medication with an opioid reformulation that
provides continuous pain relief for 3 to 14 days among surgery
patients and 30 to 90 days among patients with chronic pain; and
WHEREAS, LAIPR may combat the opioid epidemic by reducing
potential misuse or abuse among patients and reducing risks to
others by taking pills off the streets and preventing them from
being lost, stolen or given away; and
WHEREAS, LAIPR may relieve prescription opioid dependence and
withdrawal by providing consistent levels of medication over an
established time frame within the therapeutic window; and
WHEREAS, Fathom Pharma is ready to begin the approval process
for clinical trials, which are likely to take place in our
Commonwealth; therefore be it
RESOLVED, That the House of Representatives recognize Fathom
Pharma LLC for its efforts to mitigate the opioid crisis; and be
it further
RESOLVED, That the House of Representatives express support
for Fathom Pharma LLC and other innovative pharmaceutical
companies involved in developing pain medications that are
effective treatments while being difficult to divert or misuse.
20190HR0588PN2768 - 2 -
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25